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Introduction
World Health Organization (WHO) had declared infertility as a health problem on 30 th November 2009. Infertility has a definition as a reproductive system disease marked by the inability of achieving pregnancy after 12 months or more periods of sexual intercourses without the use of contraception. 1, 2 It occured on about 10-15% spouses at reproductive age in the United States (6% in North America and 3.1% in South & Middle America), 3% in Middle East, 10 .1% in Africa, 4.8% in Asia and Oceania, 2.9% in India, 2.9% in Philippines, 1.9% in Bangladesh, and 3.4% in Indonesia. [3] [4] [5] Infertility caused by female factors accounted for 28.6% to 57.5% of all cases. [6] [7] [8] [9] [10] WHO explained that anovulation infertility caused by ovulation dysfunction (WHO anovulation infertility classification class 2) appeared on 80% of cases. 11 One of the treatment to cure this condition is by ovulation induction to stimulate mature oocyte. 12 All this time, ovulation induction agent commonly used in Indonesia is clomiphene citrate. It has a relatively high ovulation success rate, approximately 50-75%, but the conception success rate is just about 10-40%. [13] [14] [15] The unconformity between ovulation and conception rate of this drug is caused by the anti-estrogen effect of clomiphene citrate which caused the thinning of endometrium layer and reducing endometrium exogenicity. [15] [16] [17] [18] [19] [20] Dehbashi et al 16 reported that the administration of clomiphene citrate affected endometrium thickness, but not its exogenicity. Gonen et al 17 found that the administration of clomiphene citrate was actually affecting endometrium thickness and exogenicity, and there was a conformity between endometrial thickness, exogenicity, and pregnancy rate. A study by Rinaldi et al 18 concluded that pregnancy rate was higher in the group with an endometrium thicker than 10 cm. Therefore, the anti-estrogen effect of clomiphene citrate was suspected as the cause of the ovulation-conception number unconformity. 15 The other promising ovulation inducing agents other than clomiphene citrate is letrozole. Letrozole is an aromatase inhibitor commonly used in breast cancer treatment. Aromatase inhibitor reduces estrogen level in breast cancer patients and inhibiting the growth of the cancer. 21 The use of letrozole as an ovulation inducing agents is promising and will improve ovulation-conception rate unconformity found on clomiphene citrate administration because letrozole has no anti-estrogen effect like clomiphene citrate. 15 Begum et al 22 proved that the endometrial layer was thicker on letrozole administration compared to clomiphene citrate (9.03±0.89mm vs 10.37±1.2mm; p<0.05). However, there were different results such as the study by Badawy et al, 24 obtaining different result on endometrial thickness between clomiphene citrate and letrozole (9.2±0.7mm vs 8.1±0.2mm; p<0.05). Disappointing result was also reported by Dehbashi et al, 23 where the endometrial thickness on either clomiphene citrate and letrozole did not show any significant difference (7.12±2.01mm vs 6.44±1.68mm; p>0.05). Although there were differences on endometrial thickness, letrozole is still considered as a promising drug because of the absence of anti-estrogenic effect. Therefore, this study is aimed to know the effectiveness of clomiphene citrate and letrozole for ovulation induction related to endometrial thickness and the number of dominant follicles between the administration of 50mg to 100mg of clomiphene citrate with 2,5mg to 5mg of letrozole.
Methods
This is a cross sectional study using medical records of patients receiving either 50mg clomiphene citrate, 100mg clomiphene citrate, 2.5mg letrozole, or 5mg letrozole at dr. Cipto Mangunkusumo National Hospital, Jakarta from January 2011-May 2015. Every treatment groups received the agent daily on 3 rd -7 th day of menstrual cycle. The inclusion criteria of the samples were women who met the diagnostic criteria for anovulation infertility, receiving either 50 mg clomiphene citrate, 100mg clomiphene citrate, 2.5mg letrozole or 5mg letrozole therapy, and have a complete USG medical record. On 12 th day of menstrual cycle, transvaginal ultrasound examination was performed to measure endometrial thickness and dominant follicle number. Ultrasonography examination was performed by expert in reproductive endocrinology. Smokers and patients receiving both clomiphene citrate and letrozole at the same time were excluded.
All numerical values were tested for their distribution normality using Kolmogorov-smirnov or Shapiro-wilk tests. Normally distributed data were expressed as mean ± standard deviation whereas non-normally distributed data were expressed as median (minimum-maximum). The comparison of numerical variables between groups were tested using one-way ANOVA and Kruskall Wallis. Independent t-test or Mann-Whitney were used for post-hoc analysis between groups. All p values <0.05 were considered statistically significant. Statistical analysis were performed using Statistical Package for Social Science (SPSS) for windows version 22. 
Results
Subjects' Characteristics
A number of 143 patients were recruited in this study. Subjects were grouped based on their treatment: 45 patients on clomiphene citrate 50mg group, 29 patients in clomiphene citrate 100mg group, 23 patients in letrozole 2.5mg group, and 46 patients in letrozol 5mg group. Characteristics of the subjects were presented in Table 1 . We classified patient's causes of infertility either male, female or idiopathic factor as shown in Table 2 . There was no difference in causes of infertility in four groups. Data were presented as mean ± standard deviation or median (minimum-maximum) Endometrial Thickness, Morphology, and Number of Dominant Follicle There was a significant difference on endometrial thickness on late-follicular phase (p<0.001) between women receiving clomiphene citrate and letrozole. However, there were no significant differences on the comparison of women receiving 2.5mg letrozole against women receiving 5mg letrozole and between women receiving 50mg clomiphene citrate and 100mg clomiphene citrate (p>0.005).
Trilaminar endometrial morphology was higher in women receiving 2.5mg and 5mg letrozole compared to those administered with 50mg and 100mg clomiphene citrate (14% and 23.1%). There was no significant difference on follicle numbers between women receiving clomiphene citrate and letrozole (Table 3) . 
Discussion
This study compared endometrial thickness, morphology, and number of dominant follicle between groups receiving different doses of either clomiphene citrate or letrozole. This study confirmed the difference of endometrial thickness and endometrium morphology between these two different type of induction agents. This was similar with previous study: letrozole yielded thicker endometrium, thus preferable for successful pregnancy. 22 However, a contrary result was noted from Maryati et al 24 study among Indonesian population with similar setting. Besides, Casper and Mitwally 25 reported that there was no difference in the number of dominant follicle between groups.
To date, clomiphene citrate is the most prescribed induction agent. However, there was a rising question about its efficacy. Although ovulation rate was quite high, the pregnancy rate was still low. This probably due to endometrial thickness and nontrilaminar morphology. Letrozole has become a center of attention as it has anti-estrogenic effect. 26 This study found that there was no difference in the given doses of induction agent. Previous report by Fadhli et al 27 found a thicker endometrium with 5mg letrozole compared to 2.5mg letrozole. Previously, successful rate in pateints who took letrozole was higher than clomiphene citrate. As clomiphene citrate remains a gold standard for therapy, Begum et al 22 found that letrozole could become a solution if they failed with clomiphene citrate.
Endometrial thickness is an important factor for successfull pregnancy after induction. However, there is a controversy on its role due to different results in many trials. In a meta-analysis, there was no difference in pregnancy rate and ovulatory cycles between letrozole and clomiphene citrate. 28 Remohi et al 29 stated that estradiol level correlated with endometrial thickness. Also, endometrial thickness correlated with implantation. However, those parameters were not a good predictors for pregnancy. There were another factors attributed for successful pregnancy, including vasculature of the subendometrium and intraendometrium. 30 The main limitation encountered in this study was unequal sample size between all groups. Besides, we could not report the effects of each treatment regarding with the neonatal outcomes.
Conclusions
This study supported that letrozole was associated with thicker endometrium and trilaminar morphology of endometrium. However, there was no significance difference in the number of dominant follicle. Further study on its efficacy toward pregnancy rate between different doses of clomiphene citrate and letrozole among Indonesian population is needed.
